Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Date:1/6/2014

or parkinsonism. Both of these scales documented minimal symptoms at baseline and there was no worsening during the six weeks of treatment. Clinical hematology, chemistry and ECG monitoring indicated no emergent safety signals.

There were no drug-drug interactions identified in subjects who were utilizing a range of psychotropic and other concomitant medications.

Next Steps for NBI-98854Data from the Kinect 2 study will be integrated with the Kinect study data to inform the ultimate design of the next study, Kinect 3. The Company will work with its consultants and scientific advisors to expand and refine the pharmacokinetic/pharmacodynamic models as well as to complete the remaining safety and efficacy analyses from both Kinect and Kinect 2. These data will form the basis for an End of Phase II briefing package along with the proposed Phase III protocol.

Kinect 2 Study DesignThe Kinect 2 Study was a randomized, parallel, double-blind, placebo-controlled, dose titration Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with an underlying mood disorder (e.g., bipolar disorder), schizophrenia or schizoaffective disorder, or a gastrointestinal disorder with exposure to metoclopramide. This 100 subject study assessed once-daily NBI-98854 over a six-week placebo-controlled dosing period. Half of the randomized subjects received placebo and half received NBI-98854. The NBI-98854 dosing regimen began with a once-daily dose of 25 mg for the initial two weeks. At the completion of the initial two weeks of dosing, based on certain efficacy and safety criteria, patients were titrated to a once-daily 50 mg dose, or continued on the once-daily 25 mg dose for the following two-week period. At the completion of the second two weeks of treatment another efficacy and safety assessment was performed and patients were eligible to be titrated to a once-daily 75 mg, 50 mg or 25 mg dose for the
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21. November 2014 Michael DeMarco ... Morgen des 14. Februar 2014 zugetragen hat. Seine Tochter ... vergessen. Video - http://youtu.be/5cVoMCe0uiE ... war, mein morgendliches Training zu machen", erzählt Michael ... der Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war ...
(Date:11/21/2014)... BEVERLY HILLS, Calif. , Nov. 20, 2014 ... Ken Eaton , the election of Anthony J. ... as President. Effective November 19, 2014, ... and member of the Board of Directors of Oxis International, ... J. Cataldo has been named Chief Executive Officer of ...
(Date:11/21/2014)... THE WOODLANDS, Texas , Nov. 21, 2014 /PRNewswire/ ... announced that it has priced its offering of $80,000,000 ... 2021 (the "Convertible Notes") in a private offering within ... Notes were offered to qualified institutional buyers pursuant to ... amended (the "Securities Act"). Lexicon has also granted the ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... ARBOR, Mich., March 19, 2012 SARC, Sarcoma Alliance ... group, announced that on Tuesday, March 20, 2012, the ... Committee (ODAC) will review two New Drug Applications submitted ... for their drugs for the treatment of sarcoma.  Sarcoma ...
... March 19, 2012  BioDelivery Sciences International, Inc. (NASDAQ: ... Annual Report on Form 10-K for the year ended ... Commission and, in connection therewith, is providing a review ... operations and upcoming milestones for 2012. (Logo:  ...
Cached Medicine Technology:FDA's Oncologic Drugs Advisory Committee to Review Two New Drug Applications for Sarcoma on Tuesday, March 20, 2012 2BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report 2BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report 3BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report 4BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report 5BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report 6BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report 7BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report 8
(Date:11/22/2014)... 2014 (HealthDay News) -- The wide variety and complexity ... threat for people with food allergies, an expert warns. ... many types of food allergies that it can be ... Dr. Guha Krishnaswamy, director of allergy and clinical immunology ... hospital news release. "If you know you have ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 This month has ... supplier, because it has received many positive reviews from some ... richness of its products by launching a new selection of ... time, global customers can enjoy free shipping and up to ... , Stylish ladies can always find the most suitable dress ...
(Date:11/22/2014)... November 22, 2014 Forbes Living ... are pleased to announce that Ashley Lombardo and friend ... contest. , Ms. Lombardo entered friend Candy Sherman ... She wrote of how her friend is courageously battling ... a single mom. Despite medical bills piling up and ...
(Date:11/22/2014)... 2014 A new technology for ... which safely detects and identifies hazards inside and ... Developed by RHT SpectraSafe, the technology avoids hazardous ... in other areas including medical, recycling, military, and ... high frequency radio waves that pass harmlessly through ...
(Date:11/22/2014)... OH (PRWEB) November 22, 2014 Wright ... for AndroGel side-effects lawsuits have been scheduled between ... Court, Northern District of Illinois. U.S. District Judge Matthew ... issued a Case Management Order (CMO) on November 6, ... deadlines for attorneys to submit documents and other activities ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... improved access to health education and benefits for ... seniors in communities across America, ... in Washington, D.C., CVS/pharmacy and the National Council on Aging,(NCOA) ... health and well-being of older Americans. Their joint,"Prescription for Better ...
... Batesville,Holdings, Inc., a wholly owned subsidiary of ... the present Batesville Casket Company,s funeral,services division, ... as Senior,Vice President Human Resources. He will ... human resources function for the new stand ...
... Accident Fund Insurance,Company of America has recognized Clark ... safe work environment. The company,recently surpassed 2 million ... 2006 the Michigan construction industry reported more,than 3,500 ... Construction,received the Gold Award from MIOSHA in 2005 ...
... ( http://www.nhs.uk ), the,digital ,front door, to the NHS, ... look after their foot health., Based on NHS ... find information about the importance of caring for your ... to treat them, plus how to,choose the correct footwear, ...
... Philadelphia City Council Acknowledges Department,s Anti-Violence,Program, ... Health and its partners were recognized today ... Injury Reporting and,Intervention System, or PIRIS, a ... Philadelphia., The system provides comprehensive intervention ...
... die from breast cancer each year because current treatments ... to stem the disease, warns Breast Cancer Campaign today. ... published today, 56 of the UKs most influential breast ... priorities for the greatest potential impact on patients. , ...
Cached Medicine News:Health News:CVS/pharmacy and the National Council on Aging Extend 'Prescription for Better Health' Partnership 2Health News:CVS/pharmacy and the National Council on Aging Extend 'Prescription for Better Health' Partnership 3Health News:Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources 2Health News:Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources 3Health News:Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources 4Health News:Accident Fund Recognizes Clark Construction Co. for 2 Million Hours without a Lost-Time Injury 2Health News:Department of Health Highlights Violence as a Public Health Issue 2Health News:Too many women still dying from breast cancer, says charity 2
... system continues the "Consensus Concept" approach ... with the diversified experience of a ... an affordable knee system that incorporates ... designed to provide both joint and ...
... The Optetrak system includes a cruciate ... Patellar flange mates with both resurfacing ... assure precise, repeatable kinematics and fit ... to reduce wear. Constant cutting guide ...
... result of more than a decade of ... on a comprehensive study of knee kinematics ... tibial insert retrieval analysis.,As a result of ... and motion patterns in total knees, the ...
... The Foundation® PS knee offers a femoral option ... cam action that engages at 60 degrees of ... motion and allow for 130 degrees of flexion. ... design with prominent lateral flare. The constrained tibial ...
Medicine Products: